He Ling, Xiao Jianghong, Wei Zhigong, He Yan, Wang Jingjing, Guan Hui, Mu Xiaoli, Peng Xingchen
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Oral Oncol. 2020 Aug 27;109:104978. doi: 10.1016/j.oraloncology.2020.104978.
To observe the differences of dosimetric parameters and late toxicities in Nasopharyngeal Carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT), which may provide the selective basis about radiation technology in clinical practices.
Dosimetric parameters and late toxicities were collected and retrospectively analyzed from 627 NPC patients (stage as I-IVA/IVB) between January 2010 and December 2015.
The median D of all targets and D of PGTVnd (regional lymph nodes) were lower in VAMT than those in IMRT, while the median D and D of PGTVnx (primary lesions) were higher in VMAT than those in IMRT (p < 0.05). Superior sparing of the organs at risk were observed in VMAT. The maximum dose of the brainstem, spinal cord, temporal lobes, temporomandibular joint, optic chiasm, and lens were lower in VMAT than those in IMRT, where the median dose reduction ranged from 0.56 to 3.56 Gy (p < 0.05). Meanwhile, the median parotid glands V in VMAT was reduced by approximately 2% compared to that in IMRT (p = 0.027). Regarding the late toxicities, ototoxicity, trismus, and temporal lobe injury were reduced by VMAT (p < 0.05). Furthermore, the late toxicities were correlative with the radiation dose of the corresponding OARs (p < 0.05).
For NPC treatment plans, the VMAT might provide not only more favorable dose distributions of targets but also better sparing of normal tissue than observed in IMRT. Furthermore, VMAT possibly provides less treatment-related late toxicities such as ototoxicity, trismus, and temporal lobe injury.
观察接受调强放疗(IMRT)或容积调强弧形放疗(VMAT)的鼻咽癌(NPC)患者剂量学参数和晚期毒性反应的差异,为临床实践中放射技术的选择提供依据。
收集并回顾性分析2010年1月至2015年12月期间627例I-IVA/IVB期NPC患者的剂量学参数和晚期毒性反应。
VMAT组所有靶区的中位剂量(D)和咽后淋巴结转移灶(PGTVnd)的D均低于IMRT组,而VMAT组原发灶(PGTVnx)的中位D和D高于IMRT组(p<0.05)。VMAT组对危及器官的保护效果更佳。VMAT组脑干、脊髓、颞叶、颞下颌关节、视交叉和晶状体的最大剂量低于IMRT组,中位剂量降低范围为0.56至3.56 Gy(p<0.05)。同时,VMAT组腮腺的中位体积较IMRT组减少约2%(p=0.027)。在晚期毒性反应方面,VMAT组的耳毒性、牙关紧闭和颞叶损伤有所减轻(p<0.05)。此外,晚期毒性反应与相应危及器官的放射剂量相关(p<0.05)。
对于NPC治疗计划,VMAT不仅可能提供更有利的靶区剂量分布,而且对正常组织的保护优于IMRT。此外,VMAT可能导致较少的与治疗相关的晚期毒性反应,如耳毒性、牙关紧闭和颞叶损伤。